AU5945801A - Opoid antagonist compositions and dosage forms - Google Patents
Opoid antagonist compositions and dosage formsInfo
- Publication number
- AU5945801A AU5945801A AU5945801A AU5945801A AU5945801A AU 5945801 A AU5945801 A AU 5945801A AU 5945801 A AU5945801 A AU 5945801A AU 5945801 A AU5945801 A AU 5945801A AU 5945801 A AU5945801 A AU 5945801A
- Authority
- AU
- Australia
- Prior art keywords
- dosage forms
- antagonist compositions
- opoid
- opoid antagonist
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56607100A | 2000-05-05 | 2000-05-05 | |
US20226800P | 2000-05-05 | 2000-05-05 | |
US20222700P | 2000-05-05 | 2000-05-05 | |
PCT/US2000/012493 WO2000067739A2 (fr) | 1999-05-06 | 2000-05-05 | Compositions et procedes permettant d'ameliorer la puissance analgesique du tramadol et d'attenuer ses effets secondaires negatifs |
US24448200P | 2000-10-30 | 2000-10-30 | |
US24511000P | 2000-11-01 | 2000-11-01 | |
US24623500P | 2000-11-02 | 2000-11-02 | |
US75633101A | 2001-01-08 | 2001-01-08 | |
PCT/US2001/014377 WO2001085257A2 (fr) | 2000-05-05 | 2001-05-04 | Compositions d'antagoniste opioide et formes de dosage |
Publications (1)
Publication Number | Publication Date |
---|---|
AU5945801A true AU5945801A (en) | 2001-11-20 |
Family
ID=38051036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU5945801A Pending AU5945801A (en) | 2000-05-05 | 2001-05-04 | Opoid antagonist compositions and dosage forms |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1284736A2 (fr) |
JP (1) | JP2004515455A (fr) |
AU (1) | AU5945801A (fr) |
CA (1) | CA2408106A1 (fr) |
WO (1) | WO2001085257A2 (fr) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274591B1 (en) | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
PT2266564E (pt) | 1997-12-22 | 2013-06-20 | Euro Celtique Sa | Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide |
BRPI0108380B8 (pt) | 2000-02-08 | 2021-05-25 | Euro Celtique S/A | fórmulas de opióides agonistas resistentes à adulteração, método para diminuir o abuso de um opióide agonista numa fórmula de dosagem oral, método de preparação de uma fórmula de dosagem oral e método de tratamento da dor |
EP1392265A2 (fr) * | 2000-10-30 | 2004-03-03 | Pain Therapeutics, Inc. | Inhibiteurs des transporteurs du medicament d'abc au niveau de la barriere hemato-encephalique |
WO2002092060A1 (fr) | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Forme posologique d'opioides a liberation prolongee empechant la consommation abusive |
WO2003002100A1 (fr) | 2001-06-26 | 2003-01-09 | Farrell John J | Systeme d'administration de narcotique inviolable |
DK1416842T3 (da) | 2001-07-18 | 2009-03-16 | Euro Celtique Sa | Farmaceutiske kombinationer af oxycodon og naloxon |
WO2003013433A2 (fr) | 2001-08-06 | 2003-02-20 | Euro-Celtique S.A. | Formulations d'antagoniste sequestre |
ATE431738T1 (de) | 2001-08-06 | 2009-06-15 | Euro Celtique Sa | Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist |
US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
CN1652752A (zh) * | 2002-03-14 | 2005-08-10 | 欧罗赛铁克股份有限公司 | 盐酸纳曲酮组合物 |
PT2425821T (pt) | 2002-04-05 | 2017-08-23 | Mundipharma Farmacêutica Lda | Preparação farmacêutica contendo oxicodona e naloxona |
DK1542658T3 (da) * | 2002-08-15 | 2011-04-04 | Euro Celtique Sa | Farmaceutiske sammensætninger omfattende et opioidanalgetikum |
ES2677769T3 (es) | 2002-09-20 | 2018-08-06 | Alpharma Pharmaceuticals Llc | Subunidad secuestrante y composiciones y procedimientos relacionados |
RU2362560C2 (ru) | 2003-04-08 | 2009-07-27 | Проджиникс Фармасьютикалз, Инк. | Фармацевтическая препаративная форма |
TWI347201B (en) | 2003-04-21 | 2011-08-21 | Euro Celtique Sa | Pharmaceutical products,uses thereof and methods for preparing the same |
MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
EP1702558A1 (fr) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Procédé et dispositif pour évaluer la fonction de l'activité intestinale |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
AU2006220682B2 (en) | 2005-03-07 | 2012-05-31 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
WO2006126529A1 (fr) | 2005-05-25 | 2006-11-30 | Shionogi & Co., Ltd. | Derive de morphinane substitue en position 7 par un carbamoyle et insature en positions 6 et 7 |
AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
CA2630624C (fr) | 2005-11-22 | 2013-08-06 | Orexigen Therapeutics, Inc. | Compositions et procedes d'augmentation de la sensibilite a l'insuline |
BRPI0619806A2 (pt) | 2005-12-13 | 2011-10-18 | Biodelivery Sciences Int Inc | dispositivo para fornecimento de fármacos transmucosal resistente ao abuso |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
ES2385612T3 (es) | 2006-06-19 | 2012-07-27 | Alpharma Pharmaceuticals, Llc | Composiciones farmacéuticas |
RS54764B1 (sr) | 2006-07-21 | 2016-10-31 | Biodelivery Sciences Int Inc | Sredstvo za transmukozalnu isporuku sa povećanim nakupljanjem |
KR20180066272A (ko) | 2006-11-09 | 2018-06-18 | 오렉시젠 세러퓨틱스 인크. | 단위 용량 팩키지 |
CA2682550C (fr) | 2007-03-29 | 2016-05-17 | Wyeth | Recepteur et antagonistes d'opioide peripheriques et utilisations de ceux-ci |
US20100305323A1 (en) | 2007-03-29 | 2010-12-02 | Smolenskaya Valeriya N | Crystal forms of (r)-n-methylnaltrexone bromide and uses thereof |
PE20090700A1 (es) | 2007-03-29 | 2009-07-13 | Progenics Pharm Inc | Compuestos heterociclicos como antagonistas del receptor opioide periferico |
US8623418B2 (en) | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
US9226907B2 (en) * | 2008-02-01 | 2016-01-05 | Abbvie Inc. | Extended release hydrocodone acetaminophen and related methods and uses thereof |
WO2009099411A1 (fr) | 2008-02-06 | 2009-08-13 | Progenics Pharmaceuticals, Inc. | Préparation et utilisation de (r),(r)-2,2'-bis-méthylnaltrexone |
CA2719134C (fr) | 2008-03-21 | 2015-06-30 | The University Of Chicago | Traitement avec des antagonistes des opioides et des inhibiteurs mtor |
CA2725930A1 (fr) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Procedes pour traiter des pathologies des graisses viscerales |
EP2306829B1 (fr) | 2008-07-01 | 2017-01-04 | University of Chicago | Particules contenant un antagoniste périphérique de récepteur d'opioïde |
CA2676881C (fr) | 2008-09-30 | 2017-04-25 | Wyeth | Antagonistes de recepteurs opioides peripheriques, et leurs utilisations |
ES2706407T3 (es) | 2009-03-10 | 2019-03-28 | Euro Celtique Sa | Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona |
MX344303B (es) | 2010-01-11 | 2016-12-13 | Orexigen Therapeutics Inc | Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor. |
US9901539B2 (en) | 2011-12-21 | 2018-02-27 | Biodelivery Sciences International, Inc. | Transmucosal drug delivery devices for use in chronic pain relief |
IL300868A (en) | 2012-06-06 | 2023-04-01 | Orexigen Therapeutics Inc | Methods for treating overweight and obesity |
NZ716267A (en) | 2013-07-23 | 2017-05-26 | Euro Celtique Sa | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
WO2015095391A1 (fr) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Comprimé extrudé anti-abus à libération prolongée |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
CA2955229C (fr) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Forme posologique remplie de liquide anti-abus a liberation immediate |
EP3209282A4 (fr) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Forme galénique anti-abus de remplissage de liquide à libération prolongée |
EP3939570A1 (fr) * | 2016-02-18 | 2022-01-19 | Immune Therapeutics, Inc. | Naltrexone pour le traitement des maladies auto-immunes et inflammatoires |
WO2021005501A1 (fr) | 2019-07-10 | 2021-01-14 | Intas Pharmaceuticals Ltd. | Formulation de naltrexone |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4889860A (en) * | 1985-09-23 | 1989-12-26 | Nova Pharmaceutical Corporation | Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists |
US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US6103258A (en) * | 1996-04-12 | 2000-08-15 | Simon; David Lew | Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics |
PT2266564E (pt) * | 1997-12-22 | 2013-06-20 | Euro Celtique Sa | Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide |
WO1999032120A1 (fr) * | 1997-12-22 | 1999-07-01 | Euro-Celtique, S.A. | Procede prevenant l'abus des doses orales d'opioides |
-
2001
- 2001-05-04 JP JP2001581910A patent/JP2004515455A/ja active Pending
- 2001-05-04 WO PCT/US2001/014377 patent/WO2001085257A2/fr active Application Filing
- 2001-05-04 CA CA002408106A patent/CA2408106A1/fr not_active Abandoned
- 2001-05-04 EP EP01932983A patent/EP1284736A2/fr not_active Withdrawn
- 2001-05-04 AU AU5945801A patent/AU5945801A/xx active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1284736A2 (fr) | 2003-02-26 |
CA2408106A1 (fr) | 2001-11-15 |
WO2001085257A2 (fr) | 2001-11-15 |
WO2001085257A3 (fr) | 2002-06-13 |
JP2004515455A (ja) | 2004-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU5945801A (en) | Opoid antagonist compositions and dosage forms | |
GB2358582B (en) | Pharmaceutical compositions | |
HUP0300582A3 (en) | Pharmaceutical compositions | |
AU6219601A (en) | Pharmaceutical compositions | |
HK1064601A1 (en) | Pharmaceutical compositions comprising amlodipene maleate | |
HUP0302455A3 (en) | Combination pharmaceutical compositions containing amplodipine and benazepril and their use | |
GB0009584D0 (en) | Pharmaceutical compositions | |
AU8576801A (en) | Pharmaceutical compositions | |
HUP0400553A3 (en) | Pharmaceutical compositions | |
HUP0303184A3 (en) | Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them | |
EP1328278A4 (fr) | Analgesique et compositions de glucosamine | |
AU1390002A (en) | Pharmaceutical compositions | |
GB0008485D0 (en) | Pharmaceutical compositions | |
HUP0303074A3 (en) | Benzodiazepine derivatives and pharmaceutical compositions them | |
IL153487A0 (en) | Pharmaceutical compositions and methods for use | |
GB0009613D0 (en) | Pharmaceutical compositions | |
GB0009609D0 (en) | Therapeutic compositions | |
GB0010806D0 (en) | Shampoo compositions | |
GB0030857D0 (en) | Therapeutic compositions | |
GB0013503D0 (en) | Pharmaceutical compositions and their uses | |
EP1402892A4 (fr) | Compositions anti-inflammatoires et antitussives | |
AU8254101A (en) | Medicinal compositions | |
GB0019768D0 (en) | Preservative compounds and compositions | |
GB0015361D0 (en) | Improvements in pharmaceutical compositions | |
GB0014420D0 (en) | Pharmaceutical compositions and their use |